Corvus Pharmaceuticals Increases At-The-Market Offering Capacity to $200 Million

summarizeSummary

Corvus Pharmaceuticals has increased the capacity of its At-The-Market (ATM) offering program to $200 million, allowing the company to sell additional common stock from time to time.

check_boxKey Events

• ATM Program Expanded

  The company amended its Open Market Sale Agreement, increasing the maximum aggregate offering price for common stock sales through Jefferies LLC from $100 million to $200 million. This reinstates and expands a program previously suspended on January 20, 2026.

• Significant Potential Dilution

  If the full $200 million is sold at an assumed price of $16.90 per share, approximately 11.8 million new shares could be issued, representing a potential dilution of about 15.8% based on shares outstanding as of December 31, 2025.

• Use of Proceeds

  Net proceeds from any sales are expected to be used for working capital and general corporate purposes, including capital expenditures, research and development, sales and marketing, and administrative expenses.

• Context of Recent Capital Raises

  This expansion follows closely on the heels of a completed $189.4 million public offering announced on March 12, 2026, indicating a sustained focus on strengthening the company's financial position.

auto_awesomeAnalysis

Corvus Pharmaceuticals has significantly expanded its potential capital-raising capabilities by amending and restating its At-The-Market (ATM) offering agreement, increasing the maximum aggregate offering price from $100 million to $200 million. This move, following the suspension of the previous ATM program on January 20, 2026, and a recently completed $189.4 million public offering on March 12, 2026, indicates a continuous and substantial need for capital. While providing financial flexibility, the potential issuance of up to $200 million in common stock represents a significant potential dilution for existing shareholders, estimated at approximately 15.8% if fully utilized at the assumed price. This substantial increase in potential share supply could create an overhang on the stock price.